Equities analysts expect STERIS plc (NYSE:STE) to report sales of $879.87 million for the current quarter, according to Zacks. Three analysts have made estimates for STERIS’s earnings, with the highest sales estimate coming in at $890.00 million and the lowest estimate coming in at $870.80 million. STERIS reported sales of $822.99 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 6.9%. The firm is expected to issue its next earnings report after the market closes on Tuesday, May 18th.
According to Zacks, analysts expect that STERIS will report full year sales of $3.11 billion for the current fiscal year, with estimates ranging from $3.10 billion to $3.12 billion. For the next year, analysts expect that the firm will post sales of $3.74 billion, with estimates ranging from $3.46 billion to $4.29 billion. Zacks’ sales calculations are a mean average based on a survey of analysts that that provide coverage for STERIS.
STERIS (NYSE:STE) last posted its earnings results on Tuesday, February 2nd. The medical equipment provider reported $1.73 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.52 by $0.21. The business had revenue of $808.90 million during the quarter, compared to the consensus estimate of $794.08 million. STERIS had a return on equity of 14.44% and a net margin of 13.97%. The business’s quarterly revenue was up 4.5% on a year-over-year basis. During the same period in the previous year, the business earned $1.45 EPS.
STE traded down $1.49 during trading on Thursday, hitting $211.98. 602,434 shares of the stock were exchanged, compared to its average volume of 635,855. The company has a quick ratio of 2.00, a current ratio of 2.64 and a debt-to-equity ratio of 0.28. STERIS has a 1-year low of $139.51 and a 1-year high of $216.74. The stock has a fifty day moving average price of $199.31 and a two-hundred day moving average price of $189.52. The firm has a market capitalization of $18.09 billion, a P/E ratio of 42.99 and a beta of 0.59.
In other news, VP Julia Madsen sold 1,000 shares of the firm’s stock in a transaction on Friday, April 23rd. The shares were sold at an average price of $215.00, for a total value of $215,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.20% of the stock is currently owned by corporate insiders.
Several hedge funds have recently modified their holdings of the company. Toews Corp ADV purchased a new stake in shares of STERIS in the first quarter valued at approximately $933,000. Envestnet Asset Management Inc. boosted its position in shares of STERIS by 4.2% during the 1st quarter. Envestnet Asset Management Inc. now owns 437,378 shares of the medical equipment provider’s stock worth $83,312,000 after purchasing an additional 17,744 shares in the last quarter. Oak Ridge Investments LLC boosted its position in shares of STERIS by 973.8% during the 1st quarter. Oak Ridge Investments LLC now owns 66,405 shares of the medical equipment provider’s stock worth $12,649,000 after purchasing an additional 60,221 shares in the last quarter. Commonwealth Equity Services LLC grew its stake in shares of STERIS by 6.4% during the 1st quarter. Commonwealth Equity Services LLC now owns 4,301 shares of the medical equipment provider’s stock worth $819,000 after purchasing an additional 260 shares during the period. Finally, Victory Capital Management Inc. increased its holdings in shares of STERIS by 1,512.7% in the 1st quarter. Victory Capital Management Inc. now owns 23,433 shares of the medical equipment provider’s stock valued at $4,463,000 after purchasing an additional 21,980 shares in the last quarter. 90.01% of the stock is owned by institutional investors and hedge funds.
STERIS plc provides infection prevention and other procedural products and services worldwide. It operates in four segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, equipment management services, and connectivity solutions.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.